Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Osteosarcoma 1Desmoid Tumors 1Colorectal Neoplasms 1

Interventions

pembrolizumab 26Paclitaxel 22Oxaliplatin 20Nivolumab 16Docetaxel 16Capecitabine 16Cisplatin 15Fluorouracil 11Cyclophosphamide 11fludarabine 10S 1 (combination) 10Trastuzumab 9Irinotecan 9Carboplatin 8Leucovorin 7tislelizumab 6aldesleukin 5Ramucirumab 5Interleukin-2 5Gemcitabine 5Drug Therapy 5Bevacizumab 5sintilimab 4fludarabine phosphate 4apatinib 4Radiotherapy 4Everolimus 4regorafenib 3olaparib 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Stomach Neoplasms × vactosertib × Clear all
NCT03724851 2025-03-25

Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

MedPacto, Inc.

Phase 1/2 Completed
120 enrolled
Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT03698825 2024-12-09

TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer

MedPacto, Inc.

Phase 1/2 Completed
62 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡